Twogee Biotech has closed a €2.16 million seed funding round. Investors include... High-Tech Founders Fund and Bavaria CapitalThe group is complemented by strategic partners such as... AgriFoodTech Venture Alliance and Heinz Entsorgung, who are supporting the Munich-based startup in its scaling efforts.
With this funding, Twogee Biotech aims to accelerate the development and commercialization of its enzyme platform. Founded in Munich in 2024, the startup develops customized enzyme solutions and production strains for industrial applications. Its goal is to make biomass by-products and residual streams economically viable and to develop them as a raw material source for industrial companies.
Side streams are biogenic materials that arise as byproducts in industrial, agricultural, or waste management processes. These include, for example, plant residues or organic waste, which until now have often been used for only limited purposes or disposed of. Twogee Biotech converts these materials into second-generation raw materials, particularly so-called 2G sugars, using enzymes.
These 2G sugars are waste-based and do not compete with food production. They serve as starting materials for chemical, bio-, and synbiological processes and can replace fossil or food-based raw materials. This gives industrial companies the opportunity to continue using existing plants while simultaneously changing their raw material base.
Frank Wallrapp, CEO of Twogee Biotech:
“Many industrial residues contain significant untapped added value. We help our partners to unlock this potential with minimal integration effort and a clear economic perspective.”
Infrastructure and team expansion
The startup is primarily investing the raised capital in expanding its infrastructure and growing its workforce. Twogee Biotech already operates its own laboratories and bioreactors at its Martinsried site near Munich. Initial minimum viable products are available, and the company is also conducting paid pilot projects with industry partners.
Helge Jochens, CTO and Co-founder:
“A significant portion of the funding will be used to expand our laboratories at the IZB with predictive bioreactor systems and to strengthen our team with experienced process and scale-up experts. This ensures that our developments are economically transferable to our customers' production scale.”
Another component of the business model is a licensing approach that also enables local enzyme production at the customer's site. This reduces costs and transport emissions and allows for the establishment of decentralized value chains.
With the completed seed funding, Twogee Biotech positions itself as a technological development partner for industrial companies that Biomass-systematically utilize side streams and gradually switch their raw material supply to low-CO2 alternatives.
